Novira Therapeutics, Inc.

Amira Pharmaceuticals, Inc.

Merck Patent Gmbh

Tempest Therapeutics, Inc.

Inception 2, Inc.

Ryan Christopher Clark

Nicholas Simon Stock

Jason Duarte Jacintho

Brian Andrew Stearns

Yalda Mostofi Bravo

Yen Truong

Austin Chen

Thomas Jon Seiders

Jeannie M Arruda

Lucy Xiumin Zhao

Deborah Volkots

Austin Chih-Yu Chen

Jill Melissa Baccei

Ruoxi Lan

Heather Renee Coate

Bijan Pedram

Catherine Jorand-LeBrun

Jill Melissa Scott

John Howard Hutchinson

Bowei Wang

David Nathan Zalatan

Yem Pham Truong

Yen Pham Truong

Catherine Jorand-Lebrun

Jason Jacintho

The invention disclosed herein is directed to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPAR&#x3b1; antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.

Triazolone compounds and uses thereof

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

Sulfide alkyl compounds for HBV treatment

Pyridyl reverse sulfonamides for HBV treatment

The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.

Heteroaryl compounds as IRAK inhibitors and uses thereof

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Polycyclic compounds as lysophosphatidic acid receptor antagonists

Compounds as lysophosphatidic acid receptor antagonists

The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPAR&#x3b1; antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a of a therapeutically effective amount of a selective PPAR&#x3b1; antagonist.

Growing community of inventors

San Diego, CA, United States of America

Ryan Christopher Clark